The Current State of Physician-Modified Endovascular Grafts in Complex Abdominal Aortic Aneurysms.

Physician-modified endografts (PMEGs) for the treatment of complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms are a viable option. Other endovascular options include custom and off-the-shelf devices for fenestrated and branched endovascular aortic repair, parallel grafts, and in situ laser fenestration. The limitations of these devices include time to development, strict anatomic criteria, and durability regarding parallel grafts.

Treatment of Kommerell's diverticulum in rare aberrant aortic arch anatomy.

A Kommerell's diverticulum (KD) is a saccular aneurysmal outpouching at the origin of an aberrant subclavian artery. Due to a lack of data in the literature, there are no standardized guidelines for management of KD, and the diverse presentation of associated aberrant anatomy complicates evaluating the best modality of treatment. We present a 74-year-old woman who had a uniquely aberrant aortic arch with an aberrant retroesophageal right subclavian artery associated with a KD and a saccular aneurysm off the left subclavian artery who was treated via a hybrid approach, demonstrating the feasibility of this treatment modality in a patient with unique aberrant arch anatomy.

Successful open repair of syphilitic thoracoabdominal aneurysm.

Most syphilitic aneurysms involve the ascending aorta. Those involving the descending aorta are less common, and those involving the abdominal aorta are unusual. Rarer yet, we present the case of a 40-year-old man with HIV and a history of syphilis with a thoracoabdominal aneurysm.

One-year outcomes after transcarotid artery revascularization (TCAR) in the ROADSTER 2 trial.

Objectives: Transcarotid artery revascularization (TCAR) is a carotid stenting technique that utilizes reversal of cerebral arterial flow to confer cerebral protection. Although carotid endarterectomy (CEA) remains the standard for treatment of symptomatic and asymptomatic carotid stenosis, the search for the optimal minimally invasive option for the high-risk surgical patient continues. The goal of the current study is to evaluate the 1-year safety and efficacy of TCAR in a prospective clinical trial.

Intravascular Lithotripsy for Treatment of Calcified Lesions During Carotid Artery Stenting.

Purpose: To report the use of intravascular lithotripsy (IVL) in the treatment of calcified carotid artery lesions.

Materials And Methods: The records of 21 high-surgical-risk patients (mean age 75.1±8.

Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease.

Background And Purpose: Transcarotid artery revascularization (TCAR) is comprised of carotid artery stent placement with cerebral protection via proximal carotid artery clamping and reversal of cerebral arterial flow. The aim of the present study was to evaluate the safety and efficacy of TCAR performed by a broad group of physicians with variable TCAR experience.

Methods: The ROADSTER 2 study is a prospective, open label, single arm, multicenter, postapproval registry for patients undergoing TCAR.

Treatment of Carotid Restenosis Using Transcarotid Revascularization.

Objective: Transcarotid artery revascularization (TCAR) using the ENROUTE Neuroprotection System (Silk Road Medical) is a United States Food and Drug Administration-approved treatment modality for stroke risk reduction in the setting of carotid artery stenosis. The goal of this investigation was to define the real-world outcomes associated with the application of this technique to patients presenting with restenosis after previous carotid endarterectomy (CEA) or transfemoral carotid artery stenting (TF-CAS).

Methods: Retrospective review of prospectively maintained institutional databases capturing all nontrial TCARs performed between August 2013 and July 2018 using the ENROUTE Neuroprotection System was completed at 3 unaffiliated hospital systems and unified for descriptive outcomes analysis.

Duration of blood flow reversal during transcarotid artery revascularization does not affect outcome.

Objective: Transcarotid artery revascularization (TCAR) has become an increasingly popular alternative for the treatment of carotid bifurcation stenosis. TCAR employs carotid blood flow reversal through an ex vivo common carotid artery to femoral vein shunt for neuroprotection during the placement and angioplasty of the carotid artery stent. There is a lack of data regarding an association between the duration of flow reversal and neurologic complications or other adverse events.

The learning curve of transcarotid artery revascularization.

Background: In the pivotal U.S. Food and Drug Administration approval trial, ROADSTER, transcarotid artery revascularization (TCAR) using the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical Inc, Sunnyvale, Calif) was shown to have one of the lowest reported complication rates, not only for carotid artery stent placement, but also for any carotid intervention, including endarterectomy.

A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy.

Objective: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions.

Clinical Outcomes and Cost Comparisons of Stent and Non-Stent Interventions in Infrainguinal Peripheral Artery Disease: Insights From the Excellence in Peripheral Artery Disease (XLPAD) Registry.

Background: The contemporary limb outcomes and costs of stent-based vs non-stent based strategies in endovascular revascularization of femoropopliteal (FP) peripheral artery disease (PAD) are not well understood.

Methods And Results: We present data from the ongoing United States multicenter Excellence in Peripheral Artery Disease Registry between 2006-2016 to compare stent vs non-stent treatment outcomes and associated costs in FP interventions. A total of 2910 FP interventions were performed in 2162 patients (mean age, 66 years), comprising 1339 stent based (superficial femoral artery, 93%) in 1007 patients and 1571 non-stent interventions (superficial femoral artery, 85%) in 1155 patients.

Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions.

Objectives: The aim of this study was to assess actual procedural costs and outcomes comparing wire-catheter and dedicated chronic total occlusion (CTO) device strategies to cross peripheral artery CTOs.

Background: Peripheral artery CTO interventions are frequently performed, but there are limited data on actual procedural costs and outcomes comparing wire-catheter and dedicated CTO devices.

Methods: The XLPAD (Excellence in Peripheral Artery Disease Intervention) registry (NCT01904851) was accessed to retrospectively compare cost and 30-day and 12-month outcomes of wire-catheter and crossing device strategies for treatment of infrainguinal peripheral artery CTO.

Stent and Non-Stent Based Outcomes of Infrainguinal Peripheral Artery Interventions From the Multicenter XLPAD Registry.

Background: There are limited data regarding contemporary use of stent and non-stent based treatment strategies of infrainguinal peripheral artery disease (PAD).

Methods: We analyzed data from the ongoing multicenter XLPAD registry between July 2005 and October 2013 to report on the use of non-stent (atherectomy ± balloon angioplasty) and stent-based treatment of superficial femoral artery (SFA), popliteal, and below-the-knee (BTK) vessels in contemporary clinical practice.

Results: A total of 584 interventions (SFA, 82.

Hybrid endovascular treatment of an anomalous right subclavian artery dissection in a patient with Marfan syndrome.

We report the case of a 26-year-old female patient with Marfan syndrome and an aberrant right subclavian artery (ARSA) with associated Kommerell diverticulum. The patient presented with spontaneous acute dissection of the ARSA that showed fusiform dilation to 4 cm in diameter. Definitive treatment was performed using a two-stage hybrid endovascular technique, including extrathoracic bilateral upper extremity bypass and thoracic endovascular aortic repair with debranching of the right and left subclavian arteries.